Levetiracetam Neuraxpharm

Levetiracetam, the active ingredient in Levetiracetam Neuraxpharm, is an anticonvulsant presented as an intravenous solution for intravenous use. It is indicated as adjunctive therapy for partial‑onset, generalized tonic‑clonic and myoclonic seizures in patients requiring additional seizure control.

GNH USA supplies Levetiracetam Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levetiracetam is an anticonvulsant used as adjunctive therapy for several seizure types.

Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic regimens. Generalized tonic‑clonic seizures: provides additional seizure control in patients not fully controlled by other drugs. Myoclonic seizures: helps decrease myoclonic jerks as part of combination therapy.

Levetiracetam is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Blood dyscrasias (e.g., neutropenia, thrombocytopenia) - Suicidal ideation or behavior - Severe skin rash - Rare respiratory depression

Levetiracetam should be used with careful clinical monitoring. - Renal impairment: assess renal function and consider dose adjustment. - Hepatic impairment: monitor liver enzymes and clinical status. - Psychiatric symptoms: observe for mood changes, agitation, or depression. - Concomitant CNS depressants: use caution due to additive sedation. - Pregnancy: risk unknown; weigh benefits against potential risks. - Store at ambient temperature: keep in original container, protect from light and moisture.

Levetiracetam may interact with other medications; monitoring is advised.

Major Interactions (Avoid): - Co‑administration with enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin) may significantly lower levetiracetam plasma levels. - Concurrent use with drugs that markedly affect renal clearance may alter exposure.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, opioids): increased sedation risk. - Antidepressants or antipsychotics: potential for behavioral changes. - Immunosuppressants: monitor for altered efficacy. - Anticoagulants: observe for any changes in bleeding risk.